Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:IMAB NASDAQ:TLSA NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.61+7.7%$1.57$1.03▼$8.64$50.04M-0.32456,876 shs126,344 shsIMABI-Mab$2.14+2.1%$1.83$0.60▼$3.08$174.83M1.4391,946 shs137,460 shsTLSATiziana Life Sciences$1.48+0.3%$1.50$0.63▼$1.91$172.35M-0.05625,943 shs97,787 shsVYGRVoyager Therapeutics$3.31+7.3%$3.19$2.65▼$9.55$183.44M0.85488,818 shs484,934 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-3.50%+5.94%+1.68%+21.20%-79.53%IMABI-Mab-1.87%-4.55%-15.66%+149.61%+28.83%TLSATiziana Life Sciences-0.68%-1.34%-5.16%+65.17%+82.56%VYGRVoyager Therapeutics-10.20%-3.14%-6.67%-1.60%-65.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals2.8013 of 5 stars3.45.00.00.02.90.00.6IMABI-Mab2.8369 of 5 stars3.73.00.00.02.41.70.6TLSATiziana Life Sciences1.1712 of 5 stars0.05.00.00.02.61.70.0VYGRVoyager Therapeutics3.8814 of 5 stars3.62.00.04.61.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00149.22% UpsideIMABI-Mab 3.33Buy$6.00179.85% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/AVYGRVoyager Therapeutics 3.13Buy$13.39305.02% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, VYGR, TLSA, and IMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/9/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AIMABI-MabN/AN/AN/AN/A$2.47 per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/AVYGRVoyager Therapeutics$66.96M2.73N/AN/A$5.49 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/AIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A8/5/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)Latest ATNM, VYGR, TLSA, and IMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025VYGRVoyager Therapeutics-$0.48N/AN/AN/A$9.50 millionN/A5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25IMABI-MabN/A22.3522.35TLSATiziana Life SciencesN/A1.021.02VYGRVoyager TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%IMABI-Mab38.38%TLSATiziana Life SciencesN/AVYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%IMABI-Mab22.10%TLSATiziana Life Sciences39.82%VYGRVoyager Therapeutics4.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableVYGRVoyager Therapeutics10055.34 million52.83 millionOptionableATNM, VYGR, TLSA, and IMAB HeadlinesRecent News About These CompaniesVoyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE ApproachJuly 16 at 7:00 AM | globenewswire.comMoon + Bird acquires Alastair Chisholm's book about NASA’s Voyager 1July 15 at 2:13 PM | thebookseller.comTEmbark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and MoreJuly 14 at 7:50 PM | prestigeonline.comPVoyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star TrekJuly 14 at 7:50 PM | fandomwire.comFUK awards AirTanker network node upgrade for VoyagerJuly 11, 2025 | janes.comJVoyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current TechnologyJuly 10, 2025 | msn.comBrokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39July 8, 2025 | americanbankingnews.comRNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'July 7, 2025 | itv.comIAtlas Announces New Canadian Arctic Expedition Aboard World VoyagerJuly 6, 2025 | cruiseindustrynews.comCWith Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-WalletsJuly 5, 2025 | travelmole.comTVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesJuly 5, 2025 | marketbeat.comAnt International launches Alipay+ Voyager, an AI-powered travel assistant inside e-walletsJuly 3, 2025 | walastech.comWVYGR Voyager Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMajor Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With PaintJune 20, 2025 | theaviationist.comTProtesters Vandalize RAF Voyager Tankers In Palestine ProtestJune 20, 2025 | aviationweek.comAVoyager Technologies Soars with IPO SuccessJune 14, 2025 | devdiscourse.comDSpace Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss ExpansionJune 12, 2025 | devdiscourse.comDVoyager Technologies Rises in Debut, Signaling Improving IPO MarketJune 12, 2025 | msn.comVoyager soars 82% on first day of trading as defense tech boomsJune 12, 2025 | msn.comInvestor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOsJune 11, 2025 | msn.comVoyager Technologies' Shares More Than Double in NYSE DebutJune 11, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNM, VYGR, TLSA, and IMAB Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.60 +0.12 (+7.72%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.I-Mab NASDAQ:IMAB$2.14 +0.04 (+2.10%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Tiziana Life Sciences NASDAQ:TLSA$1.48 +0.01 (+0.34%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Voyager Therapeutics NASDAQ:VYGR$3.31 +0.23 (+7.34%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
